News and Trends 1 Sep 2022
Provention Bio looks to advance diabetes drug through $125M loan
U.S. biopharma company Provention Bio, Inc. has secured a term loan facility of up to $125 million with Hercules Capital, Inc. ahead of the company’s potential launch of teplizumab. The…